L. J. SANDLOW, M.D.; H. A. ALLEN, M.D.; H. NECHELES, M.D., PH.D., F.A.C.P.
The introduction of fluorescent techniques in the study of tissue has provided new approaches for detecting cancer.
Rall, Loo, Lane, and Kelly (1) studied a patient with metastatic breast carcinoma who had been treated with a fluorescent riboflavin antagonist, U 6538. At autopsy, a yellow fluorescence in the tumor was noted, which persisted for days, although fluorescence of U 6538 was found to last only for a few hours. Tumors that had fluoresced were studied in other patients who had not received this drug. By a process of elimination it was found that these patients had received tetracycline.
SANDLOW LJ, ALLEN HA, NECHELES H. The Use of Tetracycline Fluorescence in the Detection of Gastric Malignancy. Ann Intern Med. ;58:409–413. doi: 10.7326/0003-4819-58-3-409
Download citation file:
Published: Ann Intern Med. 1963;58(3):409-413.
Gastric Cancer, Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use